390
Participants
Start Date
February 21, 2022
Primary Completion Date
August 2, 2027
Study Completion Date
November 1, 2032
Osimertinib
The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease recurrence, unacceptable toxicity or other discontinuation criteria are met.
Placebo
Matching placebo. Initial dose of 80mg once daily can be reduced to 40mg once daily.
Research Site, Taipei
Research Site, Taipei
Research Site, Taipei
Research Site, Taoyuan District
Research Site, La Plata
Research Site, Rosario
Research Site, Cipolletti
Research Site, S.C. de Bariloche
Research Site, New York
Research Site, New York
Research Site, Bangkok
Research Site, Bangkok
Research Site, Pulau Pinang
Research Site, White Plains
Research Site, Bangkok
Research Site, Taipei
Research Site, Flushing
Research Site, Berlin
Research Site, Bursa
Research Site, Genova
Research Site, Suwon
Research Site, Suwon
Research Site, Newark
Research Site, Milan
Research Site, Frederick
Research Site, Fort Belvoir
Research Site, Lübeck
Research Site, Málaga
Research Site, Atlanta
Research Site, Kadıkoy/Istanbul
Research Site, Izmir
Research Site, Padua
Research Site, Vigo
Research Site, Khon Kaen
Research Site, Taichung
Research Site, Taichung
Research Site, Daegu
Research Site, Parma
Research Site, Valencia
Research Site, Kuala Selangor
Research Site, Georgsmarienhütte
Research Site, Zaragoza
Research Site, Florence
Research Site, Muang
Research Site, Jinju
Research Site, Xintai
Research Site, Kuala Lumpur
Research Site, Chicago
Research Site, Bari
Research Site, Tainan City
Research Site, Esslingen am Neckar
Research Site, Houston
Research Site, Napoli
Research Site, München
Research Site, Grand Junction
Research Site, Los Angeles
Research Site, Hat Yai
Research Site, Orange
Research Site, Kuching
Research Site, Catania
Research Site, Würzburg
Research Site, Anchorage
Research Site, Hanoi
Research Site, Beijing
Research Site, Beijing
Research Site, Beijing
Research Site, Beijing
Research Site, Beijing
Research Site, Beijing
Research Site, Changchun
Research Site, Harbin
Research Site, Singapore
Research Site, Saint Petersburg
Research Site, Shanghai
Research Site, Shanghai
Research Site, Nanjing
Research Site, Suzhou
Research Site, Yangzhou
Research Site, Jinan
Research Site, Singapore
Research Site, Hangzhou
Research Site, Fuzhou
Research Site, Changsha
Research Site, Changsha
Research Site, Zhengzhou
Research Site, Guangzhou
Research Site, Guangzhou
Research Site, Shenzhen
Research Site, Chengdu
Research Site, Perm
Research Site, Ho Chi Minh City
Research Site, Hồ Chí Minh
Research Site, Xi'an
Research Site, Morristown
Research Site, Buenos Aires
Research Site, CABA
Research Site, Rosario
Research Site, Barretos
Research Site, Belo Horizonte
Research Site, Porto Alegre
Research Site, Recife
Research Site, Rio de Janeiro
Research Site, São Paulo
Research Site, São Paulo
Research Site, Vancouver
Research Site, Montreal
Research Site, Toronto
Research Site, Taiyuan
Research Site, Roma
Research Site, Chiba
Research Site, Fukuoka
Research Site, Hiroshima
Research Site, Kashiwa
Research Site, Kōtoku
Research Site, Kyoto
Research Site, Niigata
Research Site, Osaka
Research Site, Osakasayama-shi
Research Site, Sendai
Research Site, Shinjuku-ku
Research Site, Sunto-gun
Research Site, Wakayama
Research Site, Poznan
Research Site, Warsaw
Research Site, Bucharest
Research Site, Bucharest
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Barcelona
Research Site, Ankara
Research Site, Istanbul
Research Site, Birmingham
Research Site, Blackpool
Research Site, London
Research Site, London
Research Site, London
Research Site, Nottingham
Research Site, Wythenshawe
Lead Sponsor
AstraZeneca
INDUSTRY